Published in Ophthalmol Ther on May 10, 2016
Ocular Hypertension Treatment Study (OHTS) (OHTS) | NCT00000125
Combined Ranibizumab and Iluvien for Diabetic Macular Oedema (CASSIE) | NCT03784443
Clinical utility of intravitreal fluocinolone acetonide (Iluvien(®)) implant in the management of patients with chronic diabetic macular edema: a review of the current literature. Clin Ophthalmol (2017) 0.75
Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema. Patient Prefer Adherence (2017) 0.75
Report of 12-months efficacy and safety of intravitreal fluocinalone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye (Lond) (2017) 0.75
Identification of a gene that causes primary open angle glaucoma. Science (1997) 8.14
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology (2011) 4.61
The 14-year incidence of visual loss in a diabetic population. Ophthalmology (1998) 4.08
Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology (2005) 4.01
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology (2014) 3.50
The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol (1999) 3.30
EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. THE EFFECT OF DEXAMETHASONE IN THE NORMAL EYE. Arch Ophthalmol (1963) 3.13
CORTICOSTEROIDS AND INTRAOCULAR PRESSURE. Arch Ophthalmol (1963) 3.07
Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina (2011) 3.04
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol (2009) 2.84
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61
EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. II. THE EFFECT OF DEXAMETHASONE IN THE GLAUCOMATOUS EYE. Arch Ophthalmol (1963) 2.58
TOPICAL CORTICOSTEROIDS AND HEREDITY IN PRIMARY OPEN-ANGLE GLAUCOMA. Am J Ophthalmol (1964) 2.58
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
INTRAOCULAR PRESSURE RESPONSE TO TOPICAL CORTICOSTEROIDS. Invest Ophthalmol (1965) 2.39
Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol (2003) 2.39
Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology (2015) 2.39
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology (2012) 2.32
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology (2005) 2.30
Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology (2006) 2.01
Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica (1997) 1.98
Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology (2012) 1.95
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol (2010) 1.82
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology (2011) 1.79
Concern Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol (2011) 1.69
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52
The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology (2009) 1.47
Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol (1974) 1.36
Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today (2008) 1.33
Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci (2000) 1.28
Steroid-induced iatrogenic glaucoma. Ophthalmic Res (2011) 1.27
Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice. Invest Ophthalmol Vis Sci (2014) 1.26
Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv (2008) 1.24
Drug delivery to the posterior segment of the eye. Drug Discov Today (2010) 1.23
Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol (2013) 1.21
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology (2014) 1.12
Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology (2009) 1.11
Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina (2009) 1.07
Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology (2010) 1.06
A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother (2012) 1.05
A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci (2010) 1.04
Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol (2004) 1.01
Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology (2014) 0.98
Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep (2012) 0.97
Effect of Intravitreal Injection of Dexamethasone 0.7 mg (Ozurdex®) on Intraocular Pressure in Patients with Macular Edema. Ophthalmic Res (2015) 0.97
Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol (2015) 0.96
Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol (2008) 0.95
Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. Ophthalmology (2008) 0.89
Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res (2014) 0.86
Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol (2008) 0.85
A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye (Lond) (2015) 0.81
Intravitreal dexamethasone for diabetic macular edema: a pilot study. Ophthalmic Surg Lasers Imaging (2010) 0.81
Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits. Mol Vis (2014) 0.80
Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection. Invest Ophthalmol Vis Sci (2008) 0.80
A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). Br J Ophthalmol (2015) 0.79
Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. J Ocul Pharmacol Ther (2015) 0.78
INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: Pharmacokinetic Considerations. Retina (2015) 0.77
Intraocular pressure following intravitreal injection of triamcinolone acetonide. Open Ophthalmol J (2008) 0.77
[Ocular hypertension after intravitreal steroid injections: Clinical update as of 2015]. J Fr Ophtalmol (2015) 0.76
Expression of concern: Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011:129(7):914-920. JAMA Ophthalmol (2015) 0.76